Operational Costs Compared: SG&A Analysis of Geron Corporation and MiMedx Group, Inc.

SG&A Expenses: Geron vs. MiMedx Over a Decade

__timestampGeron CorporationMiMedx Group, Inc.
Wednesday, January 1, 20141675800090480000
Thursday, January 1, 201517793000133384000
Friday, January 1, 201618761000179997000
Sunday, January 1, 201719287000220119000
Monday, January 1, 201818707000258528000
Tuesday, January 1, 201920893000198205000
Wednesday, January 1, 202025678000181022000
Friday, January 1, 202129665000198359000
Saturday, January 1, 202243628000208789000
Sunday, January 1, 202369135000211124000
Loading chart...

In pursuit of knowledge

SG&A Expenses: A Tale of Two Companies

In the world of biotechnology and medical devices, operational efficiency is key. Over the past decade, Geron Corporation and MiMedx Group, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, MiMedx consistently outpaced Geron, with expenses peaking at over 250% higher in 2018. However, Geron has shown a remarkable upward trajectory, with a 312% increase in SG&A expenses from 2014 to 2023. This surge reflects Geron's strategic investments in growth and expansion. Meanwhile, MiMedx's expenses have stabilized, indicating a mature operational strategy. These trends highlight the dynamic nature of financial management in the biotech sector, where companies must balance growth with cost efficiency. As investors and stakeholders analyze these patterns, the focus remains on how these companies will leverage their operational strategies to drive future success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025